These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 20214588)

  • 1. Pharmacogenomics in drug induced liver injury.
    Andrade RJ; Agúndez JA; Lucena MI; Martínez C; Cueto R; García-Martín E
    Curr Drug Metab; 2009 Nov; 10(9):956-70. PubMed ID: 20214588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic basis of drug-induced liver injury: present and future.
    Urban TJ; Daly AK; Aithal GP
    Semin Liver Dis; 2014 May; 34(2):123-33. PubMed ID: 24879978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms of NAT2, CYP2E1, GST, and HLA related to drug-induced liver injury in indonesian tuberculosis patients.
    Perwitasari DA; Darmawan E; Mulyani UA; Vlies PV; Alffenaar JC; Atthobar J; Wilffert B
    Int J Mycobacteriol; 2018; 7(4):380-386. PubMed ID: 30531039
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jaramillo-Valverde L; Levano KS; Tarazona DD; Vasquez-Dominguez A; Toledo-Nauto A; Capristano S; Sanchez C; Tarazona-Santos E; Ugarte-Gil C; Guio H
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity.
    Singla N; Gupta D; Birbian N; Singh J
    Tuberculosis (Edinb); 2014 May; 94(3):293-8. PubMed ID: 24637014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Cai Y; Yi J; Zhou C; Shen X
    PLoS One; 2012; 7(10):e47769. PubMed ID: 23082213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.
    Tolosa L; Jiménez N; Pérez G; Castell JV; Gómez-Lechón MJ; Donato MT
    Arch Toxicol; 2018 Jan; 92(1):383-399. PubMed ID: 28762043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antituberculosis drug-induced hepatitis: risk factors, prevention and management.
    Hussain Z; Kar P; Husain SA
    Indian J Exp Biol; 2003 Nov; 41(11):1226-32. PubMed ID: 15332488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.
    Amacher DE
    Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):335-47. PubMed ID: 22288564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.
    Teixeira RL; Morato RG; Cabello PH; Muniz LM; Moreira Ada S; Kritski AL; Mello FC; Suffys PN; Miranda AB; Santos AR
    Mem Inst Oswaldo Cruz; 2011 Sep; 106(6):716-24. PubMed ID: 22012226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice.
    Aithal GP
    Liver Int; 2015 Jul; 35(7):1801-8. PubMed ID: 25809692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation.
    Roy B; Chowdhury A; Kundu S; Santra A; Dey B; Chakraborty M; Majumder PP
    J Gastroenterol Hepatol; 2001 Sep; 16(9):1033-7. PubMed ID: 11595069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.
    Boelsterli UA; Lee KK
    J Gastroenterol Hepatol; 2014 Apr; 29(4):678-87. PubMed ID: 24783247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
    Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
    Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury.
    Huang YS; Su WJ; Huang YH; Chen CY; Chang FY; Lin HC; Lee SD
    J Hepatol; 2007 Jul; 47(1):128-34. PubMed ID: 17400324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms in metabolic enzymes and susceptibility to anti-tuberculosis drug-induced hepatic injury.
    Feng FM; Guo M; Chen Y; Li SM; Zhang P; Sun SF; Zhang GS
    Genet Mol Res; 2014 Nov; 13(4):9463-71. PubMed ID: 25501156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
    Nebert DW; McKinnon RA; Puga A
    DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
    Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
    Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs.
    Chatterjee S; Lyle N; Mandal A; Kundu S
    J Clin Pharm Ther; 2010 Aug; 35(4):465-70. PubMed ID: 20853551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.